The Middle East IVD Market is expected to reach $2.15 billion by 2031 at a CAGR of 4.1% from 2024 to 2031. In vitro diagnostics (IVD) are tests performed on biological samples such as blood, saliva, and other tissues taken from the human body to detect a wide range of diseases. IVD tests are used to screen biological samples to monitor individuals’ health and prevent or diagnose diseases. These consist of various tests based on techniques such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, polymerase chain reaction (PCR), isothermal nucleic acid amplification, and next-generation sequencing. These tests can be performed in laboratories, homes, and healthcare facilities.
The growth of the Middle East IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising healthcare expenditures, growth in the aging population, and rising awareness about healthcare. However, high prices for IVD tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market.
The rising awareness regarding early disease diagnosis and increasing inclination toward personalized medicine in the UAE and Saudi Arabia are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.
Chronic diseases are often associated with the elderly population due to the declining bodily functions and immunity among this population segment. Aging is associated with progressive deterioration in the structure and functioning of organs. The elderly population is more prone to various chronic diseases. According to the World Bank, in 2022, in Iran, Saudi Arabia, and the UAE, the percentage of the elderly population out of the total population was 8%, 3%, and 2% respectively.
The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart disease are on the rise in Middle East countries. According to GLOBOCAN, in Israel, the prevalence of cancer is expected to increase to 44.2 thousand cases in 2040 from 28.7 thousand cases in 2020. Similarly, in Saudi Arabia, the prevalence of cancer is expected to increase to 60.4 thousand cases in 2040 from 27.9 thousand cases in 2020. Early detection is very important in reducing mortality in the case of cancer, improving the chances of survival, and saving on treatment costs. Various rapid diagnostic kits are used to detect cancer. The demand for IVD kits for cancer testing is expected to grow significantly in the coming years.
The growth in the geriatric population and social behaviors such as tobacco and alcohol consumption, physical inactivity, and unhealthy diets are major factors driving a steady increase in the number of people suffering from chronic diseases. The growth in the elderly population and the associated increase in the burden of chronic disease is increasing the demand for IVD testing in the Middle East.
Click here to: Get Free Sample Pages of this Report
Personalized/precision medicine uses an individual’s genomic information to offer targeted treatment. The synthesis of genes can rapidly sequence large sections of a person’s genome and aid in the formulation of precision medicine, in turn generating cost-effective alternatives for existing therapies and allowing for novel treatments in multiple areas of infectious diseases, such as sepsis, hepatitis, and cervical cancer. Personalized medicine analyzes molecules, individual genes, and networks and translates them into an overall output for the systems of the human body. In the Middle East region, the adoption of personalized medicine is increasing in the countries, such as Saudi Arabia and UAE is providing opportunity for market growth.
Personalized medicines benefit from infectious disease management practices guided by genomic information extracted from causing microbes. These medicines can tailor therapies with the best responses and highest safety margins, ensuring better patient care. Therapeutic drug monitoring tests to select drugs for resistant HIV strains are among the most widely used personalized treatment regimes.
The launch of personalized medicine programs by various government agencies in the region is driving market growth in the region. For instance, Saudi Arabia is working toward developing a genomics research infrastructure in line with its Saudi Vision 2030 initiative. The objectives of Vision 2030 are to capture the genetic blueprint in Saudi Arabia and revolutionize healthcare by enabling personalized medicine.
Based on offering, the Middle East IVD market is segmented into reagents and kits, instruments, and software & services. In 2024, the kits & reagents segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the frequent use of reagents and kits in the detection of various chronic diseases, the commercial availability of a diverse range of reagents and consumables for the diagnosis of various diseases, ease of use of reagents & kits, and emerging threat of infectious diseases. For instance, according to WHO, between 2012 and October 2022, 2,600 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been identified, of which 84% (2,193/2,600) have been reported in Saudi Arabia. Thus, the emerging threat of infectious diseases is increasing the demand for kits & reagents for rapid testing.
Based on technology, the Middle East IVD market is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, point-of-care (POC) diagnostics, whole blood glucose monitoring, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies. In 2024, the molecular diagnostics segment is expected to account for the largest share of the market. The growing prevalence of infectious diseases, technological innovations, and the advantages of molecular diagnostics tests, such as cost-effectiveness, rapid results, and high sensitivity and specificity over laboratory tests
Additionally, the strategic initiatives adopted by key players in the region are expected to support the largest share of the segment. In June 2021, G42 Healthcare (UAE) signed a Memorandum of Understanding (MoU) with Seegene Inc. (South Korea) to offer fully equipped mobile diagnostics and testing laboratories across the Middle East and North Africa (MENA) region. The partnership was aimed at providing the Seegene Mobile Station, a laboratory-on-wheels facility to provide optimized molecular diagnosis and tests across MENA, including the UAE, Algeria, Morocco, Tunisia, Libya, Egypt, Sudan, Palestine, Jordan, Syria, Iraq, Iran, Pakistan, Lebanon, Kuwait, Qatar, Oman, Saudi Arabia, Bahrain, and Yemen.
Based on application, the Middle East in vitro diagnostics (IVD) market is segmented into infectious diseases, oncology, diabetes, cardiology, nephrology, autoimmune disorders, and other applications. The cardiology segment is expected to register the highest CAGR during the forecast period. Cardiovascular diseases (CVD) remain the leading cause of death globally. IVD testing is used for biomarker detection in cardiology. The early-stage biomarkers of CVD can potentially save many lives and help alleviate the global burden of CVD. The increasing prevalence of cardiovascular diseases, the growing global geriatric population, and increasing research on cardiac biomarkers are expected to drive the growth of this segment.
Based on diagnostic approach, the Middle East IVD market is segmented into laboratory testing, OTC/self-testing, and point-of-care testing. In 2024, the laboratory testing segment is expected to account for the largest share of the market. The large market share of this segment is primarily attributed to its higher accuracy and reliability, lower costs, and availability of several IVD tests in laboratory settings. Additionally, the laboratory testing landscape is changing in Middle East countries; due to emerging threats of epidemics, governments, along with interest groups are working to increase the rate of laboratory testing in the region. For instance, in February 2023, GC Labs (South Korea) is planning to expand its network of diagnostic laboratories in the UAE and increase access to lab testing in the country.
Based on end user, the Middle East in vitro diagnostics (IVD) market is segmented into diagnostic laboratories, hospitals & clinics, home healthcare, and other end users, which include nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories. The hospitals & clinics segment is expected to register the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to the increasing number of hospitalizations due to various diseases requiring diagnosis and the rise in the number of hospitals and clinics in the region, leading to growth in the utilization of diagnostic products. For instance, as of 2022, in UAE, the number of private medical facilities reached 4,482, including 56 hospitals and 55,208 licensed medical professionals (Source: Dubai Healthcare City Authority).
Saudi Arabia is expected to register the highest CAGR during the forecast period. The highest CAGR of this regional market is attributed to the rising healthcare expenditure, the growing aging population, and the increasing adoption of self-testing. Additionally, the rising chronic and infectious diseases are increasing the demand for IVD. Chronic diseases such as ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and cancer are responsible for most deaths in Saudi Arabia. For example, in 2021, 4.3 million people aged 20–79 years were living with diabetes in Saudi Arabia. This number grew with a CAGR of 3.4% (from 2011–2021) from 2.8 million in 2011 (Source: IDF Diabetes Atlas 2021). Thus, the demand for IVD glucose testing is increasing in the country.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy).
|
Particular |
Details |
|
Number of Pages |
~200 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
4.1% |
|
Estimated Market Size (Value) |
$2.15 billion by 2031 |
|
Segments Covered |
By Offering
By Technology
By Application
By Diagnostic Approach
By End User
|
|
Countries Covered |
Saudi Arabia, UAE, Qatar, Kuwait, Oman, Israel, and the Rest of the Middle East |
|
Key Companies |
The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy). |
The Middle East IVD market is segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. The Middle East IVD market studied in this report involves the value analysis of various segments and sub-segments of in-vitro diagnostics at regional and country levels.
The Middle East IVD market is projected to reach $2.15 billion by 2031 at a CAGR of 4.1% from 2024 to 2031.
The kits & reagents segment is estimated to account for the largest share of the Middle East IVD market in 2024. Factors such as the high burden of diseases, the high adoption of rapid diagnostic test kits, and the presence of initiatives supporting early disease diagnosis are responsible for the largest market share.
Based on the technology, the molecular diagnostics segment is projected to create more traction owing to the technological innovations and the advantages of rapid immunoassay tests, such as cost-effectiveness, rapid results, and high sensitivity & specificity over laboratory tests.
Based on application, the cardiology segment is projected to create more traction during the forecast period due to the growing burden of cardiovascular diseases and rising demand for early diagnosis.
Based on end user, the hospitals & clinics segment is projected to create more traction during the forecast period due to a large number of hospitalizations due to various diseases, the rising geriatric population, increasing healthcare access & expenditure, and the rising prevalence of healthcare-associated infections (HAIs).
The growth of the Middle East IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising awareness regarding early disease diagnosis, rising healthcare expenditures, and increasing funding for research activities. The rising awareness regarding early disease diagnosis and increasing inclination toward personalized medicine in the UAE and Saudi Arabia are expected to create growth opportunities for the players operating in this market.
The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Saudi Arabia is expected to offer significant growth opportunities owing to the government initiatives to improve the healthcare infrastructure in the country, the rising prevalence of infectious diseases, and the growth in the geriatric population.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Chronic and Infectious Diseases
4.2.2. Growing Demand for Point-of-Care and Rapid Diagnostics
4.2.3. Rising Healthcare Expenditure
4.2.4. Growth in Aging Population
4.3. Restraints
4.3.1. High Prices for IVD Tests
4.3.2. Variance in Test Results Observed in Rapid IVD Tests
4.4. Opportunities
4.4.1. Increasing Inclination Towards Personalized Medicine in UAE and Saudi Arabia
4.4.2. Rising Awareness Regarding Early Disease Diagnosis
4.5. Challenges
4.5.1. Concerns Pertaining to False Positive Results in Immunoassays and POC
4.6. Trends
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Porters Five Force Analysis
4.9.1. Bargaining Power of Buyers
4.9.2. Bargaining Power of Suppliers
4.9.3. Threat of Substitute
4.9.4. Threat of New Entrant
4.9.5. Degree of Competition
5. Middle East In Vitro Diagnostics Market Assessment—by Offering
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments
5.4. Software & Services
6. Middle East In Vitro Diagnostics Market Assessment—by Technology
6.1. Overview
6.2. Molecular Diagnostics
6.2.1. Polymerase Chain Reaction (PCR)
6.2.2. Hybridization
6.2.3. Isothermal Nucleic Acid Amplification Technology
6.2.4. DNA Sequencing & Next-generation Sequencing
6.2.5. Microarrays
6.2.6. Mass Spectrometry
6.2.7. Other Molecular Diagnostic Technologies
6.3. Point of Care Diagnostics
6.3.1. Lateral Flow Assays/Rapid Tests
6.3.2. PoC Molecular Diagnostics
6.3.3. Other POC
6.4. Immunoassay/Immunochemistry
6.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
6.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
6.4.3. Western Blotting
6.4.4. Radioimmunoassay
6.5. Biochemistry/Clinical Chemistry
6.5.1. Metabolic Panels
6.5.2. Electrolyte Panels
6.5.3. Liver Panels
6.5.4. Lipid Profiles
6.5.5. Renal Profiles
6.5.6. Thyroid Function Panels
6.6. Whole Blood Glucose Monitoring
6.7. Hematology
6.8. Microbiology
6.9. Coagulation & Hemostasis
6.10. Urinalysis
6.11. Other IVD Technologies
7. Middle East In Vitro Diagnostics Market Assessment—by Application
7.1. Overview
7.2. Infectious Diseases
7.2.1. COVID-19 Testing
7.2.2. Sexually Transmitted Diseases Testing
7.2.3. Healthcare-associated Infections
7.2.4. Hepatitis
7.2.5. HIV
7.2.6. Tropical Diseases
7.2.7. Influenza
7.2.8. Respiratory Infections (Excluding Influenza)
7.2.9. Other Infectious Diseases
7.3. Oncology
7.4. Cardiology
7.5. Diabetes
7.6. Autoimmune Disorders
7.7. Nephrology
7.8. Other Applications
8. Middle East In Vitro Diagnostics Market Assessment—by Diagnostic Approach
8.1. Overview
8.2. Lab Testing
8.3. OTC/Self-testing
8.4. Point-of-care Testing
9. Middle East In Vitro Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Home Healthcare
9.5. Other End Users
10. Middle East In Vitro Diagnostics Market Assessment—by Country/Region
10.1. Overview
10.2. Saudi Arabia
10.3. UAE
10.4. Qatar
10.5. Kuwait
10.6. Oman
10.7. Israel
10.8. Rest of Middle East
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Ranking (2023)
12. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Abbott Laboratories
12.2. Becton, Dickinson and Company
12.3. BioMérieux S.A.
12.4. Danaher Corporation
12.5. F. Hoffmann-La Roche
12.6. QIAGEN N.V.
12.7. Siemens Healthineers AG
12.8. Thermo Fisher Scientific Inc.
12.9. Bio-Rad Laboratories, Inc.
12.10. Illumina, Inc.
12.11. QuidelOrtho Corporation
12.12. Agilent Technologies Inc.
12.13. DiaSorin S.p.A.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Middle East In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 2 Middle East In Vitro Diagnostics Reagents & Kits Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Middle East In Vitro Diagnostics Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Middle East In Vitro Diagnostics Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Middle East In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 6 Middle East Molecular Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 7 Middle East Molecular Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Middle East Polymerase Chain Reaction Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Middle East Hybridization Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Middle East Isothermal Nucleic Acid Amplification Technology Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Middle East DNA Sequencing & Next-Generation Sequencing Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Middle East Microarrays Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Middle East Mass Spectrometry Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Middle East Other Molecular Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Middle East Point-of-care Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 16 Middle East Point-of-care Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Middle East Point-of-care Diagnostics Market for Lateral Flow Assays/Rapid Tests, by Country/Region, 2022–2031 (USD Million)
Table 18 Middle East Molecular POC Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Middle East Other Point-of-care Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Middle East Immunoassay/Immunochemistry Market, by Type, 2022–2031 (USD Million)
Table 21 Middle East Immunoassay/Immunochemistry Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Middle East Enzyme-linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Middle East Enzyme-linked Immunospot Assays (ELISPOT) Market, by Country/Region, 2022–2031 (USD Million)
Table 24 Middle East Western Blotting Market, by Country/Region, 2022–2031 (USD Million)
Table 25 Middle East Radioimmunoassay Market, by Country/Region, 2022–2031 (USD Million)
Table 26 Middle East Biochemistry/Clinical Chemistry Market, by Type, 2022–2031 (USD Million)
Table 27 Middle East Biochemistry/Clinical Chemistry Market, by Country/Region, 2022–2031 (USD Million)
Table 28 Middle East Metabolic Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Middle East Electrolyte Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 30 Middle East Liver Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 31 Middle East Lipid Profiles Market, by Country/Region, 2022–2031 (USD Million)
Table 32 Middle East Renal Profiles Market, by Country/Region, 2022–2031 (USD Million)
Table 33 Middle East Thyroid Functional Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 34 Middle East Whole Blood Glucose Monitoring Market, by Country/Region, 2022–2031 (USD Million)
Table 35 Middle East Microbiology Market, by Country/Region, 2022–2031 (USD Million)
Table 36 Middle East Hematology Market, by Country/Region, 2022–2031 (USD Million)
Table 37 Middle East Coagulation and Hemostasis Market, by Country/Region, 2022–2031 (USD Million)
Table 38 Middle East Urinalysis Market, by Country/Region, 2022–2031 (USD Million)
Table 39 Middle East Other IVD Technologies Market, by Country/Region, 2022–2031 (USD Million)
Table 40 Middle East In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 41 Middle East In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 42 Middle East In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 43 Middle East In Vitro Diagnostics Market for COVID-19 Testing, by Country/Region, 2022–2031 (USD Million)
Table 44 Middle East In Vitro Diagnostics Market for Sexually Transmitted Diseases Testing, by Country/Region, 2022–2031 (USD Million)
Table 45 Middle East In Vitro Diagnostics Market for Healthcare-associated Infections, by Country/Region, 2022–2031 (USD Million)
Table 46 Middle East In Vitro Diagnostics Market for Hepatitis, by Country/Region, 2022–2031 (USD Million)
Table 47 Middle East In Vitro Diagnostics Market for Tropical Diseases, by Country/Region, 2022–2031 (USD Million)
Table 48 Middle East In Vitro Diagnostics Market for Influenza, by Country/Region, 2022–2031 (USD Million)
Table 49 Middle East In Vitro Diagnostics Market for Respiratory Infections (Excluding Influenza), by Country/Region 2022–2031 (USD Million)
Table 50 Middle East In Vitro Diagnostics Market for Other Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 51 Middle East In Vitro Diagnostics Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 52 Middle East In Vitro Diagnostics Market for Diabetes, by Country/Region, 2022–2031 (USD Million)
Table 53 Middle East In Vitro Diagnostics Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 54 Middle East In Vitro Diagnostics Market for Nephrology, by Country/Region, 2022–2031 (USD Million)
Table 55 Middle East In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2022–2031 (USD Million)
Table 56 Middle East In Vitro Diagnostics Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 57 Middle East In Vitro Diagnostics Market, by Diagnostic Approach, 2022–2031 (USD Million)
Table 58 Middle East In Vitro Diagnostics Market for Laboratory Testing, by Country/Region, 2022–2031 (USD Million)
Table 59 Middle East In Vitro Diagnostics Market for OTC/Self-testing, by Country/Region, 2022–2031 (USD Million)
Table 60 Middle East In Vitro Diagnostics Market for Point-of-care Testing, by Country/Region, 2022–2031 (USD Million)
Table 61 Middle East In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 62 Middle East In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
Table 63 Middle East In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 64 Middle East In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2022–2031 (USD Million)
Table 65 Middle East In Vitro Diagnostics Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 66 Saudi Arabia In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 67 Saudi Arabia In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 68 Saudi Arabia In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 69 Saudi Arabia In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 70 Saudi Arabia In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 71 Saudi Arabia In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 72 Saudi Arabia In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 73 Saudi Arabia In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 74 Saudi Arabia In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 75 Saudi Arabia In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 76 UAE In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 77 UAE In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 78 UAE In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 79 UAE In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 80 UAE In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 81 UAE In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 82 UAE In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 83 UAE In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 84 UAE In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 85 UAE In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 86 Qatar In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 87 Qatar In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 88 Qatar In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 89 Qatar In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 90 Qatar In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 91 Qatar In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 92 Qatar In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 93 Qatar In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 94 Qatar In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 95 Qatar In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 96 Kuwait In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 97 Kuwait In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 98 Kuwait In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 99 Kuwait In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 100 Kuwait In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 101 Kuwait In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 102 Kuwait In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 103 Kuwait In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 104 Kuwait In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 105 Kuwait In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 106 Oman In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 107 Oman In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 108 Oman In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 109 Oman In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 110 Oman In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 111 Oman In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 112 Oman In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 113 Oman In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 114 Oman In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 115 Oman In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 116 Israel In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 117 Israel In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 118 Israel In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 119 Israel In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 120 Israel In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 121 Israel In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 122 Israel In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 123 Israel In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 124 Israel In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 125 Israel In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 126 Rest of Middle East In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 127 Rest of Middle East In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 128 Rest of Middle East In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 129 Rest of Middle East In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 130 Rest of Middle East In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 131 Rest of Middle East In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 132 Rest of Middle East In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 133 Rest of Middle East In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 134 Rest of Middle East In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 135 Rest of Middle East In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 136 Recent Developments, by Company (2020-2024)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Middle East In Vitro Diagnostics Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 8 Middle East In Vitro Diagnostics Market, by Technology, 2024 VS. 2031 (USD Million)
Figure 9 Middle East In Vitro Diagnostics Market, by Application, 2024 VS. 2031 (USD Million)
Figure 10 Middle East In Vitro Diagnostics Market, by Diagnostic Approach, 2024 VS. 2031 (USD Million)
Figure 11 Middle East In Vitro Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 12 Middle East In Vitro Diagnostics Market, by Country/Region
Figure 13 Factors Affecting Market Growth
Figure 14 Middle East In Vitro Diagnostics Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 15 Middle East In Vitro Diagnostics Market, by Technology, 2024 VS. 2031 (USD Million)
Figure 16 Middle East In Vitro Diagnostics Market, by Application, 2024 VS. 2031 (USD Million)
Figure 17 Middle East In Vitro Diagnostics Market, by Diagnostic Approach, 2024 VS. 2031 (USD Million)
Figure 18 Middle East In Vitro Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 19 Middle East In Vitro Diagnostics Market, by Country/Region, 2024 VS. 2031 (USD Million)
Figure 20 Middle East: In Vitro Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players, 2020—2023
Figure 22 Middle East In Vitro Diagnostics Market: Competitive Benchmarking, by Offering
Figure 23 Middle East In Vitro Diagnostics Market: Competitive Dashboard
Figure 24 Middle East In Vitro Diagnostics Market: Market Share Analysis (2023)
Figure 25 Abbott Laboratories: Financial Snapshot (2022)
Figure 26 Becton, Dickinson and Company: Financial Snapshot (2022)
Figure 27 bioMérieux SA: Financial Snapshot (2022)
Figure 28 Danaher Corporation: Financial Snapshot (2022)
Figure 29 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2022)
Figure 30 QIAGEN N.V.: Financial Snapshot (2022)
Figure 31 Siemens Healthineers AG: Financial Snapshot (2022)
Figure 32 Thermo Fisher Scientific Inc.: Financial Snapshot (2022)
Figure 33 Bio-Rad Laboratories, Inc.: Financial Snapshot (2022)
Figure 34 Illumina, Inc.: Financial Snapshot (2022)
Figure 35 QuidelOrtho Corporation: Financial Snapshot (2022)
Figure 36 Agilent Technologies Inc.: Financial Snapshot (2023)
Figure 37 DiaSorin S.p.A.: Financial Snapshot (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
Published Date: Dec-2023
Published Date: Aug-2023
